# CA209-9DJ (NCT03520491)

> A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

No report yet. It can be ordered.

- Drugs tested: nivolumab; nivolumab plus ipilimumab
- Indication: cisplatin-ineligible muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03520491
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Bladder Cancer
- Interventions: Nivolumab; Ipilimumab; Radical cystectomy
- Enrollment: 52
- Primary outcome: number of patients who proceed to radical cystectomy and pelvic lymph node dissection (RC-PLND)

## Indexed commentary on CA209-9DJ so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ca209-9dj-nct03520491
